Derriford Research Facility


Welcome to the Derriford Research Facility, the new headquarters of the University of Plymouth’s Institute of Translational and Stratified Medicine (ITSMed). This landmark £17 million investment by the University in to its biomedical research infrastructure, will provide state-of-the-art laboratories and a rich, collaborative environment for University researchers and our partners.

Opening this year, this exciting new facility, located adjacent to the main Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD) building and neighbouring Plymouth Hospitals NHS Trust, is part of the University’s £27 million investment in medical research to accelerate translation into patient care and improved outcomes for people living with devastating conditions.

From brain tumours to vaccines, tissue regeneration to hepatitis, antibiotic resistance to innovative therapies for cancer, the DRF will bring together the University of Plymouth’s medical, dental and biomedical laboratory-based research under one roof facilitating enhanced interdisciplinary working and clinical collaboration with colleagues at Derriford Hospital.

The investment in the Derriford Research Facility reflects our commitment to being a research-led Faculty in a research-led University and can only result in research findings which will have immense benefit to global health, putting health research from Plymouth on the international map and providing impressive research-based teaching facilities for our students.

Professor Robert Sneyd
Dean of the Plymouth University Peninsula Schools of Medicine and Dentistry

Derriford Research Facility staff directory

Meet the researchers who will be based at the new facility

View our staff directory

Research at the DRF

This facility will form part of our flagship Institute of Translational and Stratified Medicine (ITSMED), where research into the development of new therapeutics, diagnostics, interventions and preventative approaches is driven by our Biomedical Research Group and Clinical Trials and Population Studies Group, focusing on our core research themes of Cancer, Clinical Neuroscience and Infection, Immunity, Inflammation and cross-cutting Diagnostics, Clinical Trials and Public Health research.

The DRF will house the Plymouth University Systems Biology Centre, providing genomic and proteomic analysis facilities and expertise to support delivery of PUPSMD’s research and for other University and commercial partners. In addition, the new facility will feature high specification in vitro cell and tissue culture facilities to support the application of our unique cell model technologies and expertise.

Professor Oliver Hanemann
Director, Institute of Translational and Stratified Medicine (ITSMED)

Development progress

With construction partner Kier, in the Derriford Research Facility we are developing research laboratories and teaching space which will place medical, dental and biomedical research in Plymouth on the world map.

Support the Derriford Research Facility

Our scientists are successful at securing funding from traditional sources of research grants, but we also recognise the importance of and are grateful for donations from interested individuals, charities, businesses and other organisations.

With an impressive list of health conditions under investigation, supporting the Derriford Research Facility is an ideal opportunity to ensure that your donation goes towards a health issue dear to you. It is also a good opportunity to support world class research within the South West.

More information about ways to support the Derriford Research Facility.

PhD post supported by local fundraising

Foram Dave has a masters degree in biotechnology from VNSGU in India and a masters degree in molecular medicine from Brunel University, London. She has come to Plymouth University Peninsula Schools of Medicine and Dentistry with a wealth of research experience gained in India and in the UK.

Her research project focuses on the NF2-related, nervous system tumours such as schwannomas, meningiomas and ependymomas, characterized by the deficiency of tumour suppressor merlin.

Find out more about Foram Dave